Resistencia antimicrobiana a Escherichia coli y Pseudomonas aeruginosa de un Hospital de nivel III-E, enero – abril 2018

dc.contributor.advisorQuispe Díaz, Iván Miguel
dc.contributor.authorCórdova Rodríguez, Elva Araceli
dc.date.accessioned2023-11-10T14:45:23Z
dc.date.available2023-11-10T14:45:23Z
dc.date.issued2021
dc.description.abstractEl presente trabajo tuvo como objetivo evaluar el perfil de resistencia antimicrobiana a Escherichia coli y Pseudomonas aeruginosa de un hospital de nivel III-E, enero-abril 2018. Para dicho estudio se recolectaron los informes de microbiología de las historias clínicas de pacientes hospitalizados en el servicio de Medicina Interna (11C) del Hospital Nacional Edgardo Rebagliati Martins durante el periodo enero-abril 2018. En lo referente a susceptibilidad bacteriana se encontró que Pseudomonas aeruginosa presentó una sensibilidad de 13,60% para amikacina, 10,40% para tobramicina, imipenem/cilastatina y colistina, seguido de 9,60% para gentamicina. Asimismo, Escherichia coli se reportó una sensibilidad de 10,12% para imipenem, 9,52% para ertapenem, 8,93% para meropenem, 8,33% para nitrofurantoína, seguido de 7,74% para amikacina. El perfil de resistencia antimicrobiana encontrada para Pseudomonas aeruginosa mostró tasas de 18.18% para norfloxacino, 14,55% para levofloxacino, 12,73% para gentamicina, seguido de 10,91% para meropenem e imipenem/cilastina. Frente a Escherichia coli se constató una elevada resistencia de 12,71% para levofloxacino, 11,86% para ciprofloxacino, 11,02% para norfloxacino, seguido de 8,47% para tobramicina y ácido nalidíxico.
dc.description.abstractABSTRACT The objective of the present work was to evaluate the profile of antimicrobial resistance to Escherichia coli and Pseudomonas aeruginosa in a level III-E hospital, January-April 2018. for this study the microbiology reports of the medical records of hospitalized patients in the Internal Medicine service were collected (11C) of the Edgardo Rebagliati Martins National Hospital during the period JanuaryApril 2018. Regarding bacterial susceptibility, it was found that Pseudomonas aeruginosa presented a sensitivity of 13.60% for amikacin, 10.40% for tobramycin, imipenem / cilastatin and colistin, followed by 9.60% for gentamicin. Likewise, Escherichia coli reported a sensitivity of 10.12% for imipenem / cilastine, 9.52% for ertapenem, 8.93% for meropenem, 8.33% for nitrofurantoin, followed by 7.74% for amikacin. The antimicrobial resistance profile found for Pseudomonas aeruginosa showed rates of 18.18% for norfloxacin, 14.55% for levofloxacin, 12.73% for gentamicin, followed by 10.91% for meropenem and imipenem / cilastine. Against Escherichia coli, a high resistance of 12.71% was found for levofloxacin, 11.86% for ciprofloxacin, 11.02% for norfloxacin, followed by 8.47% for tobramycin and nalidixic acid.
dc.formatapplication/pdf
dc.identifier.urihttps://hdl.handle.net/20.500.14414/19450
dc.language.isoes
dc.publisherUniversidad Nacional de Trujillo
dc.publisher.countryPE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceUniversidad Nacional de Trujillo
dc.sourceRepositorio Institucional UNITRU
dc.subjectResistencia bacteriana, Escherichia coli, Pseudomonas aeruginosa
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.01.05
dc.titleResistencia antimicrobiana a Escherichia coli y Pseudomonas aeruginosa de un Hospital de nivel III-E, enero – abril 2018
dc.typeinfo:eu-repo/semantics/bachelorThesis
dc.type.versioninfo:eu-repo/semantics/publishedVersion
renati.advisor.dni42221001
renati.advisor.orcidhttps://orcid.org/0000-0001-8515-0654
renati.author.dni45056758
renati.discipline917046
renati.jurorMantilla Rodríguez, Ana Elena
renati.jurorQuispe Díaz, Iván Miguel
renati.jurorMarin Tello, Carmen Luisa
renati.levelhttp://purl.org/pe-repo/renati/level#tituloProfesional
renati.typehttp://purl.org/pe-repo/renati/type#tesis
thesis.degree.disciplineFarmacia
thesis.degree.grantorUniversidad Nacional de Trujillo. Facultad de Farmacia y Bioquímica
thesis.degree.nameQuímico Farmacéutico
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Cordova Rodriguez Elva Araceli.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: